Suzetrigine – complimentary MARA Rating report: pricing & reimbursement risk assessment for neuropathic pain.
This complimentary MARA Rating® report reviews Suzetrigine’s access profile in the treatment of neuropathic pain. The therapy was assigned a MARA Score of 2.43 out of 4, translating to a Marginal (B++) rating. By comparison, the 5-year neurology average stands at 2.9 and the overall industry average at 3.0, indicating that Suzetrigine falls below both benchmarks.
Clinical Effectiveness: B++ (Marginal)
In trials for painful diabetic peripheral neuropathy (DPN), Suzetrigine demonstrated short-term efficacy similar to pregabalin, a widely used standard therapy. However, results in lumbosacral radiculopathy (LSR) showed no advantage over placebo, which raises concerns about consistency across neuropathic pain subtypes.
The absence of long-term efficacy data further weakens confidence in its clinical strength.
Comparator Selection: A+ (Very Strong)
Trials included both pregabalin and placebo as comparators, reflecting accepted standards of care. This choice increases the reliability of the results and ensures they are meaningful for clinical practice comparisons.
Care-Pathway Integration: A++ (Excellent)
The therapy can be introduced into existing neuropathic pain management without requiring new diagnostic tools or major treatment adjustments. Its oral formulation and minimal monitoring needs make it straightforward to adopt in routine practice.
About MARA Rating®
The MARA Rating synthesizes ten dimensions of market access risk – clinical efficacy, health-economic value, safety profile, comparator robustness, budget impact, and more – each scored on a seven-level scale (A++ to C).
We apply evidence-based weightings to generate a single risk score. A high MARA Score (A to A++) signals strong access prospects; a low score (B++ to C) denotes elevated pricing and reimbursement hurdles.
Unlock Premium Insights
Explore seven additional domains – Quality of Life (HRQoL), Cost-Effectiveness, Safety, Patient Population, Resource Use & Cost Implications, Evidence Quality, and Uncertainty – available exclusively in Premium Insights at mararating.com.
Full Premium Report available upon request: Visit mararating.com or email sales@mararating.com to learn more and unlock your access.
Access this report and hundreds of others: https://mararating.com/mara-ratings-list.
Disclaimer: The MARA Rating® is an independent opinion of a drug’s market-access risk profile and is provided for informational purposes only – not as investment, medical, legal or any other type of advice. See our full disclaimer at mararating.com.